Open AccessExpert recommendations on the role of macrolides in chronic respiratory diseases
Author(s) -
Raja Dhar,
Deepak Talwar,
Virendra Singh,
Harjit Dumra,
Sujeet Rajan,
Jindal Sk
Publication year - 2021
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_498_19
Subject(s) - medicine , intensive care medicine , guideline , systematic review , randomized controlled trial , clinical trial , diffuse panbronchiolitis , medline , antibiotics , pathology , erythromycin , microbiology and biotechnology , political science , law , biology
India contributes to 32% of the total global disability-adjusted life years, due to chronic respiratory diseases. This has led to a high rate of health loss from these diseases. Antibiotics are commonly used in the management of respiratory disorders. With excellent tissue penetration, prolonged tissue persistence, and favorable side effect profile, macrolides are one of the best treatment options being recommended for respiratory, urogenital, dermal, and other bacterial infections. Still, there is a lack of clinical trial data on the use of macrolides in the management of respiratory chronic disease, and hence, there is a need for clinical guidance on their use in Indian setting.